SG11202004373RA - Sustained release peptide formulations - Google Patents

Sustained release peptide formulations

Info

Publication number
SG11202004373RA
SG11202004373RA SG11202004373RA SG11202004373RA SG11202004373RA SG 11202004373R A SG11202004373R A SG 11202004373RA SG 11202004373R A SG11202004373R A SG 11202004373RA SG 11202004373R A SG11202004373R A SG 11202004373RA SG 11202004373R A SG11202004373R A SG 11202004373RA
Authority
SG
Singapore
Prior art keywords
sustained release
peptide formulations
release peptide
formulations
sustained
Prior art date
Application number
SG11202004373RA
Inventor
Michael Dey
Jaya Gautam
Barton Henderson
Markus Johnsson
Stina Lindman
Original Assignee
Rhythm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhythm Pharmaceuticals Inc filed Critical Rhythm Pharmaceuticals Inc
Publication of SG11202004373RA publication Critical patent/SG11202004373RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202004373RA 2017-11-15 2018-11-15 Sustained release peptide formulations SG11202004373RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762586643P 2017-11-15 2017-11-15
PCT/US2018/061375 WO2019099735A1 (en) 2017-11-15 2018-11-15 Sustained release peptide formulations

Publications (1)

Publication Number Publication Date
SG11202004373RA true SG11202004373RA (en) 2020-06-29

Family

ID=66539115

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004373RA SG11202004373RA (en) 2017-11-15 2018-11-15 Sustained release peptide formulations

Country Status (16)

Country Link
US (1) US20210169965A1 (en)
EP (1) EP3710041A4 (en)
JP (2) JP2021502983A (en)
KR (1) KR20200135280A (en)
CN (1) CN112188898A (en)
AR (1) AR113885A1 (en)
AU (1) AU2018370039A1 (en)
BR (1) BR112020009648A2 (en)
CA (1) CA3082708A1 (en)
IL (1) IL274689A (en)
MX (1) MX2020005117A (en)
RU (1) RU2020119425A (en)
SG (1) SG11202004373RA (en)
TW (1) TW201922278A (en)
UY (1) UY37969A (en)
WO (1) WO2019099735A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62701B1 (en) 2011-12-29 2022-01-31 Rhythm Pharmaceuticals Inc Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
BR112019011053A2 (en) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc complement activity modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412530D0 (en) * 2004-06-04 2004-07-07 Camurus Ab Formulation
ES2309766T3 (en) 2004-06-04 2008-12-16 Camurus Ab SLOW RELEASE LIQUID FORMULATIONS.
ES2618315T3 (en) 2007-05-25 2017-06-21 Ipsen Pharma S.A.S. Hydantoin-modified melanocortin receptor ligands
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) * 2007-08-22 2007-10-03 Camurus Ab Formulations
CA2836847C (en) * 2011-05-25 2021-06-29 Camurus Ab Controlled release peptide formulations
KR101494594B1 (en) * 2011-08-30 2015-02-23 주식회사 종근당 Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same
RS62701B1 (en) 2011-12-29 2022-01-31 Rhythm Pharmaceuticals Inc Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
RU2019116003A (en) * 2013-03-15 2019-07-17 Ритм Фармасьютикалз, Инк. PHARMACEUTICAL COMPOSITIONS
KR20170099978A (en) * 2014-12-23 2017-09-01 카무러스 에이비 Controlled-release formulation
CN108601816A (en) * 2015-09-30 2018-09-28 节奏制药公司 Treating melanocortin-4 receptor path is associated the method for illness

Also Published As

Publication number Publication date
IL274689A (en) 2020-06-30
CN112188898A (en) 2021-01-05
WO2019099735A1 (en) 2019-05-23
TW201922278A (en) 2019-06-16
EP3710041A1 (en) 2020-09-23
EP3710041A4 (en) 2021-08-18
JP2024026333A (en) 2024-02-28
KR20200135280A (en) 2020-12-02
JP2021502983A (en) 2021-02-04
US20210169965A1 (en) 2021-06-10
UY37969A (en) 2019-06-28
BR112020009648A2 (en) 2020-11-10
AR113885A1 (en) 2020-06-24
MX2020005117A (en) 2020-11-24
AU2018370039A1 (en) 2020-05-21
CA3082708A1 (en) 2019-05-23
RU2020119425A (en) 2021-12-15

Similar Documents

Publication Publication Date Title
IL273541A (en) Formulations
IL268697A (en) Formulations
IL268920A (en) Peptide vaccines
IL269630A (en) Niraparib formulations
IL269621A (en) Niraparib formulations
IL273282A (en) Niraparib formulations
HK1258803A1 (en) Lisinopril formulations
PL3582627T3 (en) Storage-stable formulations
GB201707189D0 (en) Novel formulations
GB201707188D0 (en) Novel formulations
IL275735A (en) Sustained release olanzapine formulations
IL274689A (en) Sustained release peptide formulations
IL271673A (en) Enhanced solubility drug-containing formulations
GB201707187D0 (en) Novel formulations
GB2541483B (en) Antimicrobial peptide formulations
IL277466A (en) Peptide-containing formulations
IL269403A (en) Sustained release olanzapine formulations
IL271908A (en) Hypercompressed pharmaceutical formulations
IL272167A (en) Hemopexin formulations
PL3638211T3 (en) Delayed sustained release pharmaceutical compositions
GB2563597B (en) Improved Insecticide Formulations
IL254075A (en) Durable pest-repelling formulations
IL268195A (en) Solid fosmetpantothenate formulations
GB201714461D0 (en) Formulations
GB201716291D0 (en) Novel formulations